Information on New Approvals and Medication Safety
Search results for: heart disease
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Don’t Get Lost in Translation: Helping rheumatology Patients with Limited English Skills
Helping rheumatology patients with limited English skills
Within Our Reach–Funded Research May Hold Key to Unlocking the CNS and Suppressing RA
Studies recently published in Arthritis & Rheumatism show that a key chemical produced by the central nervous system (CNS) decreases inflammation and suppresses production of proteins known to play a role in rheumatoid arthritis (RA). This opens the way for developing a novel class of drugs that mimic this effect of the CNS on RA.
Coding Corner Question
October’s Coding Challenge
Coding Corner Question
September’s Coding Challenge
The Journey Home
Volunteering offered an opportunity to help in the present and revisit the past
Tailor the Message for Arthritis Self-Care
Delving into patients’ perceptions of self-management activities
Drug Updates
Information on New Approvals and Medication Safety
Diagnosis: Myopathy
Presentation and evaluation of metabolic causes
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 78
- Next Page »